Question 1

What specific benefits do you think this trial could offer me compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer clinical trial (NCT03532217). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer clinical trial (NCT03532217). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the possible side effects of the treatments involved?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer clinical trial (NCT03532217). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer clinical trial (NCT03532217). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my cancer progresses during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer clinical trial (NCT03532217). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any other treatment options available that I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer clinical trial (NCT03532217). Contact the study team or your healthcare provider for specific answers.

What this study is about